414 related articles for article (PubMed ID: 17910618)
1. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
Justesen US; Fox Z; Pedersen C; Cahn P; Gerstoft J; Clumeck N; Losso M; Peters B; Obel N; Castagna A; Dragsted UB; Lundgren JD;
Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):339-44. PubMed ID: 17910618
[TBL] [Abstract][Full Text] [Related]
2. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S
Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336
[TBL] [Abstract][Full Text] [Related]
4. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
[TBL] [Abstract][Full Text] [Related]
5. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J;
Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099
[TBL] [Abstract][Full Text] [Related]
7. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
[TBL] [Abstract][Full Text] [Related]
8. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J
Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863
[TBL] [Abstract][Full Text] [Related]
10. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen.
Isaac A; Taylor S; Cane P; Smit E; Gibbons SE; White DJ; Drake SM; Khoo S; Back DJ
J Antimicrob Chemother; 2004 Aug; 54(2):498-502. PubMed ID: 15254024
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.
Dragsted UB; Gerstoft J; Youle M; Fox Z; Losso M; Benetucci J; Jayaweera DT; Rieger A; Bruun JN; Castagna A; Gazzard B; Walmsley S; Hill A; Lundgren JD;
Antivir Ther; 2005; 10(6):735-43. PubMed ID: 16218173
[TBL] [Abstract][Full Text] [Related]
14. Saquinavir/Ritonavir: its evolution and current treatment role.
O'Brien WA
AIDS Read; 2006 Jan; 16(1):38-44; discussion 43. PubMed ID: 16433471
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.
von Hentig N; Nisius G; Lennemann T; Khaykin P; Stephan C; Babacan E; Staszewski S; Kurowski M; Harder S; Haberl A
Antivir Ther; 2008; 13(8):1039-46. PubMed ID: 19195329
[TBL] [Abstract][Full Text] [Related]
16. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
van der Lugt J; Lange J; Avihingsanon A; Ananworanich J; Sealoo S; Burger D; Gorowara M; Phanuphak P; Ruxrungtham K
Antivir Ther; 2009; 14(7):1001-4. PubMed ID: 19918104
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
Dragsted UB; Gerstoft J; Pedersen C; Peters B; Duran A; Obel N; Castagna A; Cahn P; Clumeck N; Bruun JN; Benetucci J; Hill A; Cassetti I; Vernazza P; Youle M; Fox Z; Lundgren JD;
J Infect Dis; 2003 Sep; 188(5):635-42. PubMed ID: 12934178
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults.
van der Lugt J; Autar RS; Ubolyam S; Garcia EF; Sankote J; Avihingsanon A; Chuenyam T; Cooper DA; Lange J; Phanuphak P; Wit F; Ruxrungtham K; Burger D;
J Antimicrob Chemother; 2008 May; 61(5):1145-53. PubMed ID: 18285316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
